Module

HBV Treatment Guidelines: Questions and Controversies

Source: Hepatitis Annual Update 2004

HBV Treatment Guidelines: Questions and Controversies


Program Director: John P. Phair, MD

Faculty:

  • Anna S. F. Lok, MD

CME CREDIT INFORMATION

Release Date: 09/10/04

Expiration Date: 09/09/05


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss treatment options for acute and chronic hepatitis

  • Discuss indications for treatment of acute and chronic hepatitis

  • Review the purpose of treatment guidelines and how guidelines are developed


Content includes:

  • Creating Guidelines
  • What Are the Goals of Treatment?
  • Who Should Be Treated?
  • HBeAg-negative Patients
  • What Should Be the Optimal Treatment?
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.